Skip to content

Hospital Wearable Defibrillator Inpatient Study

Hospital Wearable Defibrillator Inpatient Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02122549
Acronym
HWD
Enrollment
59
Registered
2014-04-24
Start date
2014-04-30
Completion date
2015-07-31
Last updated
2017-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In-Hospital Cardiac Arrest

Keywords

In-Hospital Cardiac Arrest, Telemetry

Brief summary

This study will obtain device-human interaction evaluations for the HWD1000 within the controlled environment of the hospital as well as establish that the safety profile is similar to outpatient wearable cardioverter-defibrillators use.

Detailed description

A multi-center prospective study of hospitalized patients whom a physician deems at risk of sudden cardiac arrest during the hospitalization period, wearing the HWD1000 hospital wearable defibrillator in order to evaluate caregiver and patient interactions with the device. In addition, ECG signal quality will be reviewed to confirm the HWD1000 safety profile.

Interventions

DEVICEHWD1000

Wearable cardioverter-defibrillator designed for inpatient use

Sponsors

Zoll Medical Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients whom a physician deems at risk of sudden cardiac arrest during the hospitalization period (patients will be monitored using the hospital's telemetry system). Specific inclusion criteria are: * Hospitalized patients having continuous independent ECG monitoring. * Patients at risk of sudden cardiac arrest during the hospitalization period as determined by the investigating physician. * Patient ≥18 years of age (over the legal age of providing consent).

Exclusion criteria

* Patients with an active implantable cardioverter-defibrillator. * Patients with an active unipolar pacemaker. * Patients with physical or mental conditions preventing them from interacting with or wearing the device as determined by the investigating physician. * Patients having an advanced directive prohibiting resuscitation. * Patients having bandages or other clinical condition preventing the HWD use. * Patients unable to consent. * Patients having recently experienced an arrhythmic storm. * Patients prone to paroxysmal supraventricular tachycardia.

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Time Rhythm Monitoring by the HWD1000 is Compromised Due to ECG Noise.24 hours or longerThe amount of time that the HWD1000 is unable to monitor the subject's rhythm status is the primary safety measure. The specific goals are that average monitoring will be inhibited by noise no greater than 2% of the time worn (at least 24 hours) and monitoring using single lead analysis will be no greater than 5% of the time worn (at least 24 hours).

Countries

United States

Participant flow

Participants by arm

ArmCount
HWD1000
Subjects using HWD1000 HWD1000: Wearable cardioverter-defibrillator designed for inpatient use
59
Total59

Baseline characteristics

CharacteristicHWD1000
Age, Continuous55.5 Years
STANDARD_DEVIATION 11.8
Sex: Female, Male
Female
15 Participants
Sex: Female, Male
Male
44 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 59
other
Total, other adverse events
0 / 59
serious
Total, serious adverse events
0 / 59

Outcome results

Primary

Percentage of Time Rhythm Monitoring by the HWD1000 is Compromised Due to ECG Noise.

The amount of time that the HWD1000 is unable to monitor the subject's rhythm status is the primary safety measure. The specific goals are that average monitoring will be inhibited by noise no greater than 2% of the time worn (at least 24 hours) and monitoring using single lead analysis will be no greater than 5% of the time worn (at least 24 hours).

Time frame: 24 hours or longer

Population: Subjects who wore the HWD 1000 for a minimum of 24 hours.

ArmMeasureGroupValue (MEAN)Dispersion
HWD1000Percentage of Time Rhythm Monitoring by the HWD1000 is Compromised Due to ECG Noise.Neither lead used for monitoring0.53 percentage of time wornStandard Deviation 0.73
HWD1000Percentage of Time Rhythm Monitoring by the HWD1000 is Compromised Due to ECG Noise.One lead not used for monitoring2.54 percentage of time wornStandard Deviation 3.16

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026